You're correct trader0670. They want to first know the side effects before giving it to older patients. Standard for these kind of drugs. If everything goes well, they could be in ph2 before end of the year. As weightbayou pointed out, this could trigger a milestone?
Dr. M stated a while back, that their deal with GSK, had some non clinical milestones with it. So we can see at anytime a nice development.